| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 12 |
| 1 | CYCLOPHOSPHAMIDE | 9 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 9 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 9 |
| 4 | IDECABTAGENE VICLEUCEL | 9 |
| 5 | BOSENTAN | 8 |
| 6 | OMEPRAZOLE MAGNESIUM | 8 |
| 7 | ASPIRIN | 7 |
| 8 | ATORVASTATIN CALCIUM | 7 |
| 9 | OMEPRAZOLE | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IDECABTAGENE VICLEUCEL | 9 | 0.0073 |
| 1 | TRIMIPRAMINE MALEATE | 2 | 0.0051 |
| 2 | BENZOCAINE AND DEXTROMETHORPHAN HYDROBROMIDE | 1 | 0.0040 |
| 3 | BENZOCAINE AND MENTHOL | 1 | 0.0038 |
| 4 | FENOFIBRIC ACID | 2 | 0.0026 |
| 5 | BREXUCABTAGENE AUTOLEUCEL | 4 | 0.0019 |
| 6 | CHORIONIC GONADOTROPIN | 1 | 0.0018 |
| 7 | CETYLPYRIDINIUM CHLORIDE | 1 | 0.0015 |
| 8 | LISOCABTAGENE MARALEUCEL | 1 | 0.0011 |
| 9 | ELAFIBRANOR | 1 | 0.0011 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 19 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 14 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 13 |
| 3 | HMG-CoA Reductase Inhibitor [EPC] | 12 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 12 |
| 5 | Proton Pump Inhibitor [EPC] | 11 |
| 6 | Alkylating Drug [EPC] | 10 |
| 7 | Benzodiazepine [EPC] | 9 |
| 8 | Osmotic Laxative [EPC] | 9 |
| 9 | Aromatase Inhibitor [EPC] | 8 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Peroxisome Proliferator-activated Receptor Agonist [EPC] | 1 | 0.0011 |
| 1 | CD19-directed Chimeric Antigen Receptor [EPC] | 4 | 0.0004 |
| 2 | mu-Opioid Receptor Agonist [EPC] | 1 | 0.0003 |
| 3 | Osmotic Diuretic [EPC] | 1 | 0.0002 |
| 4 | Oxazolidinone Antibacterial [EPC] | 5 | 0.0002 |
| 5 | CD52-directed Cytolytic Antibody [EPC] | 3 | 0.0002 |
| 6 | Dopamine-2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 8 | Peroxisome Proliferator Receptor alpha Agonist [EPC] | 6 | 0.0001 |
| 9 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 5 | 0.0001 |